http://www.asm.org/modules/mod_image_show_gk4/cache/Science Advisor Slidegk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/World AIDS Day Bannergk-is-651.pnglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Amy Chang Bannergk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/2016.Kavli Slide Submitgk-is-651.jpglink
http://www.asm.org/modules/mod_image_show_gk4/cache/Governance Hero Bannergk-is-651.jpglink
0 1 2 3 4
Progress bar
02-12-2016Science Advisor
02-12-2016World AIDS Day
02-12-2016Amy Chang
02-12-2016Kavli Submit
02-12-2016Nominate
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Antibacterial Development Conference
REGISTER

 

Dr. Hazuda's research on the HIV-1 integrase enzyme catalyzed the identification of viral integration inhibitors, the validation of this mechanism in vivo, and the understanding of mechanisms of resistance. These accomplishments resulted in the development and approval of raltegravir (tradename ISENTRESS), the first integrase inhibitor licensed for treatment of HIV-1 infection.

TPL_asm2013_SEARCH

91033